BIOPHARMA
ByCan Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience Into 2026?
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare Diseases Into 2026?
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology, Immunology, and MedTech Into 2026 and Beyond?
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver Disease Into 2026 and Beyond?
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
